Riboxin tablets p / o 200mg, No. 50

It is prescribed for adults in the complex therapy of ischemic heart disease, after myocardial infarction, cardiac arrhythmias caused by the use of cardiac glycosides.

Prescribed for hepatitis, cirrhosis, fatty liver disease caused by alcohol or drugs, and urocoproporphyria.

Assign to adults inside, before meals.

The daily dose for oral administration is 0.6-2.4 g. In the first days of treatment, the daily dose is 0.6-0.8 g (200 mg 3-4 times a day). In case of good tolerance, the dose is increased (for 2-3 days) to 1.2 g (0.4 g 3 times a day), if necessary - up to 2.4 g a day.

The duration of the course is from 4 weeks to 1.5-3 months.

With urocoproporphyria, the daily dose is 0.8 g (200 mg 4 times a day). The drug is taken daily for 1-3 months.

Active ingredient: inosine - 200 mg

Excipients : potato starch 54.1 mg, methylcellulose 3.2 mg, sucrose 10 mg, stearic acid 2.7 mg.

Shell composition: yellow opadry II (polyvinyl alcohol, titanium dioxide, talc, macrogol 3350 (polyethylene glycol 3350), iron (III) oxide, aluminum varnish based on quinoline yellow) - 8 mg.

Hypersensitivity to the drug, gout, hyperuricemia.

Fructose intolerance and glucose / galactose malabsorption syndrome or sucrase / isomaltase deficiency.

With care: renal failure, diabetes mellitus.

Film-coated tablets from light yellow to yellow-orange, round, biconvex, slightly rough; the cross section shows two layers: the core is white or white with a slightly yellowish tinge and the shell is from light yellow to yellow-orange.

Composition:

Active ingredient: inosine - 200 mg

Excipients : potato starch 54.1 mg, methylcellulose 3.2 mg, sucrose 10 mg, stearic acid 2.7 mg.

Shell composition: yellow opadry II (polyvinyl alcohol, titanium dioxide, talc, macrogol 3350 (polyethylene glycol 3350), iron (III) oxide, aluminum varnish based on quinoline yellow) - 8 mg.

Clinical and pharmacological group: A drug that normalizes myocardial metabolism, reduces tissue hypoxia

Pharmaco-therapeutic group: Metabolic agent

pharmachologic effect

Inosine belongs to a group of drugs that regulate metabolic processes. The drug is a precursor for the synthesis of purine nucleotides: adenosine triphosphate and guanosine triphosphate.

It has antihypoxic, metabolic and antiarrhythmic effects. Increases the energy balance of the myocardium, improves coronary circulation, prevents the consequences of intraoperative renal ischemia. It takes a direct part in the metabolism of glucose and promotes the activation of metabolism in conditions of hypoxia and in the absence of adenosine triphosphate.

It activates the metabolism of pyruvic acid to ensure the normal process of tissue respiration, and also promotes the activation of xanthine dehydrogenase. Stimulates the synthesis of nucleotides, enhances the activity of some enzymes of the Krebs cycle. Penetrating into cells, it increases the energy level, has a positive effect on metabolic processes in the myocardium, increases the strength of heart contractions and promotes more complete relaxation of the myocardium in diastole, resulting in an increase in the stroke volume of blood.

Reduces platelet aggregation, activates tissue regeneration (especially the myocardium and the mucous membrane of the gastrointestinal tract.

Pharmacokinetics

Well absorbed in the gastrointestinal tract. It is metabolized in the liver with the formation of glucuronic acid and its subsequent oxidation. Excreted by the kidneys in small quantities

Indications

It is prescribed for adults in the complex therapy of ischemic heart disease, after myocardial infarction, cardiac arrhythmias caused by the use of cardiac glycosides.

Prescribed for hepatitis, cirrhosis, fatty liver disease caused by alcohol or drugs, and urocoproporphyria.

Dosage regimen

Assign to adults inside, before meals.

The daily dose for oral administration is 0.6-2.4 g. In the first days of treatment, the daily dose is 0.6-0.8 g (200 mg 3-4 times a day). In case of good tolerance, the dose is increased (for 2-3 days) to 1.2 g (0.4 g 3 times a day), if necessary - up to 2.4 g a day.

The duration of the course is from 4 weeks to 1.5-3 months.

With urocoproporphyria, the daily dose is 0.8 g (200 mg 4 times a day). The drug is taken daily for 1-3 months.

Side effect

Allergic reactions are possible in the form of urticaria, pruritus, skin flushing (withdrawal of the drug is required). Rarely, drug treatment increases the concentration of uric acid in the blood and exacerbation of gout (with prolonged use).

Contraindications for use

Hypersensitivity to the drug, gout, hyperuricemia.

Fructose intolerance and glucose / galactose malabsorption syndrome or sucrase / isomaltase deficiency.

With care: renal failure, diabetes mellitus.

Application during pregnancy and lactation

The safety of using Riboxin during pregnancy and lactation has not been established. The use of the drug Riboxin is contraindicated during pregnancy. During treatment with Riboxin, breastfeeding should be discontinued.

Application for impaired renal function

With caution: renal failure.

special instructions

During the period of treatment with Riboxin, the concentration of uric acid in the blood and urine should be monitored.

Information for patients with diabetes mellitus: 1 tablet of the drug corresponds to 0.00641 bread units.

Does not affect the ability to drive vehicles and control mechanisms that require increased concentration.

Drug interactions

Immunosuppressants (azathioprine, antilympholine, cyclosporine, thymodepressin, etc.), when used simultaneously, reduce the effectiveness of Riboxin.

Storage conditions

In a dry, dark place at a temperature not exceeding 25 ? C. Keep out of the reach of children.

Shelf life is 3 years.

Do not use after the expiration date printed on the package.

Terms of sale

The drug is available with a prescription.